Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

Sinopharm Vaccine Approved for Emergency Use By W.H.O.
Published on: 2021-05-08
Share to
User Rating: / 0
PoorBest 

The World Health Organization (WHO) approved a COVID-19 vaccine from China’s state-owned drugmaker Sinopharm for emergency use on Friday, a boost to Beijing’s push for a big role in inoculating the world.
 

The vaccine, one of two main Chinese coronavirus vaccines that have been given to hundreds of millions of people in China and elsewhere, is the first developed by a non-Western country to win WHO backing.
 

It is also the first time the WHO has given emergency use approval to a Chinese vaccine for any infectious disease. Earlier this week, separate WHO experts had expressed concern about the quality of data the company provided on side effects.
 

A WHO emergency listing is a signal to national regulators that a product is safe and effective. It also allows it to be included in COVAX, a global programme to provide vaccines mainly for poor countries, which has hit supply problems.
 

The WHO had already given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson and, last week, Moderna.
 

世卫组织将中国国药新冠疫苗列入“紧急使用清单”

5月7日,世卫组织宣布,将中国国药集团的一款新冠疫苗列入世卫组织紧急使用清单,这款疫苗成为列入世卫组织紧急使用清单的第六款疫苗。
 

世卫组织总干事谭德塞在当天的记者会上说,世卫组织将中国国药集团中国生物北京生物制品研究所研发的一款疫苗列入紧急使用清单,这款疫苗满足世卫组织有关新冠疫苗安全性、有效性及其质量的标准。谭德塞说,这将使世卫组织主导的“新冠肺炎疫苗实施计划”(COVAX)可以采购国药集团新冠疫苗,增强相关国家药品监管机构批准这款疫苗的信心,加快国药集团疫苗进口和接种速度。

世卫组织此前已紧急授权使用数款新冠疫苗,包括美国辉瑞制药公司和德国生物新技术公司联合研发的疫苗、英国阿斯利康制药公司和牛津大学联合研发的疫苗、美国强生公司旗下杨森制药公司研发的疫苗、美国莫德纳公司研发的新冠疫苗等。国药集团的新冠疫苗是列入世卫组织紧急使用清单的首款灭活疫苗。据悉,中国科兴公司研制的一款新冠疫苗也已进入世卫组织紧急使用授权评估的最后阶段。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2024 BusinessTianjin.com. All rights reserved.